Increasing Access to Biosimilars Act of 2023
Official title: A bill to require the Secretary of Health and Human Services to establish a demonstration project to increase access to biosimilar biological products under the Medicare program.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Finance.
Increasing Access to Biosimilars Act of 2023
This bill requires the Centers for Medicare & Medicaid Services to establish a demonstration project to evaluate the benefits of providing additional payments to providers of biosimilars under Medicare. Specifically, under the demonstration project, participating providers receive an additional payment based on the difference between the costs to the provider of furnishing the biosimilar and the cost if the provider had furnished the underlying reference biological product instead.
- Introduced in Senate Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). S. 3934: Increasing Access to Biosimilars Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-3934/
"S. 3934: Increasing Access to Biosimilars Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-3934/.
S. 3934, 118th Cong. (2026), https://openamerica.io/bill/118-S-3934/.
[S. 3934: Increasing Access to Biosimilars Act of 2023](https://openamerica.io/bill/118-S-3934/)